Infliximab (anti-TNF-alpha)

Product Name： Infliximab biosimilar

CAS No.:   170277-31-3                               

Formula:  C₆₄₂₈H₉₉₁₂N₁₆₉₄O₁₉₈₇S₄₆                            

Molecular Weight：149 kDa                    

Type:   Purified immunoglobulin                      

Target： TNF alpha
Antibody Form:  Purified immunoglobulin
Physical Form:  Solution
Storage:  -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Description

Infliximab biosimilar is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab biosimilar is produced by a recombinant cell line cultured by suspension culture and is purified by a series of steps that includes measures to inactivate and remove viruses. 

Biological Activity
Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.

For research use only. Not for use in humans